Belite Bio (NASDAQ: BLTE) posts 2025 Form 20-F and audited results online

Rhea-AI Filing Summary

Belite Bio, Inc has made its annual report on Form 20-F, which includes audited consolidated financial statements for the year ended December 31, 2025, available through its website. Shareholders can request a hard copy of the report free of charge.

The company is a clinical-stage drug developer targeting degenerative retinal diseases such as Stargardt disease type 1 and geographic atrophy in dry age-related macular degeneration. Its lead oral candidate, tinlarebant, has completed a Phase 3 trial in adolescent STGD1 and is in ongoing Phase 2/3 and Phase 3 studies.

Key Figures

Financial year covered: Year ended December 31, 2025 Announcement date: March 31, 2026

2 metrics

Financial year covered Year ended December 31, 2025 Period of audited consolidated financial statements in Form 20-F

Announcement date March 31, 2026 Date Belite Bio announced Form 20-F availability

Key Terms

Form 20-F, Form 6-K, Nasdaq Listing Rule 5250(d)(1)(C), clinical-stage drug development company, +2 more

6 terms

Form 20-F regulatory

"its annual report on Form 20-F, containing audited consolidated financial statements"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

Form 6-K regulatory

"This Report on Form 6-K shall be deemed to be incorporated by reference"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Nasdaq Listing Rule 5250(d)(1)(C) regulatory

"This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C)."

NASDAQ Listing Rule 5250(d)(1)(c) is a regulatory requirement that forces a listed company to notify the exchange and the public when it has missed or will miss required SEC filings or other disclosure obligations that affect investors’ ability to evaluate the business. Think of it like a shop putting up a public notice when its financial records are late—the rule flags potential governance or reporting problems that can increase uncertainty, trading volatility, and the risk of regulatory action or delisting, so investors watch it as an early warning sign.

clinical-stage drug development company financial

"Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics"

Phase 3 trial medical

"The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects"

A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.

geographic atrophy (GA) medical

"geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD)"

A progressive eye disease that causes patches of cells in the central retina to die, creating permanent blind spots and gradual loss of sharp, detailed vision. Investors watch it because it represents a large, unmet medical need with clear clinical measures and potential for new treatments, approvals, and long-term sales; think of it as a growing blind spot on a camera that companies are trying to repair or slow down.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-41359

Belite Bio, Inc

(Exact name of registrant as specified in its charter)

Not Applicable

(Translation of Registrant´s name into English)

12750 High Bluff Drive Suite 475,

San Diego, CA 92130

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

On March 31, 2026, Belite Bio, Inc issued a press release entitled “Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website”. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933, and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit 99.1 — Press Release

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Belite Bio, Inc
	By:	/s/ Yu-Hsin Lin
	Name:	Yu-Hsin Lin
	Title:	Chief Executive Officer and Chairman

Date: March 31, 2026

Exhibit 99.1 

Belite Bio Announces Availability of Annual Report on Form 20-F

Through Company Website

SAN DIEGO, March 31, 2026 - Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 31, 2026, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:

Jennifer Wu

ir@belitebio.com

Julie Fallon

belite@argotpartners.com

FAQ

What did Belite Bio (BLTE) announce in this Form 6-K?

Belite Bio announced that its annual report on Form 20-F, including audited consolidated financial statements for the year ended December 31, 2025, is available on its website. Shareholders can also request a hard copy of the report free of charge from the company.

Where can Belite Bio (BLTE) shareholders access the 2025 Form 20-F?

Shareholders can access Belite Bio’s Form 20-F for the year ended December 31, 2025 through the company’s website at https://www.belitebio.com. The company also offers to provide a hard copy of the annual report without charge upon shareholder request.

What period do Belite Bio’s audited financial statements cover in the new Form 20-F?

The audited consolidated financial statements included in Belite Bio’s Form 20-F cover the year ended December 31, 2025. These statements form part of the company’s annual report now available online and by free hard-copy request for interested shareholders.

What is Belite Bio’s main therapeutic focus as described in the filing?

Belite Bio is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases. These include Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration, as well as certain metabolic diseases, reflecting an emphasis on significant unmet medical needs.

Which clinical trials for tinlarebant are highlighted by Belite Bio (BLTE)?

Belite Bio notes that its lead oral candidate tinlarebant has completed a Phase 3 trial called DRAGON in adolescent Stargardt disease type 1. Tinlarebant is also being evaluated in the Phase 2/3 DRAGON II trial in adolescent STGD1 and the Phase 3 PHOENIX trial in geographic atrophy.

Why does Belite Bio reference Nasdaq Listing Rule 5250(d)(1)(C)?

The company states that the press release about its Form 20-F availability is issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C). This indicates the disclosure aligns with Nasdaq requirements for timely public notice of the filing and availability of the company’s annual report to investors.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 5.1 KB